Krilogy Financial LLC Takes Position in Natera, Inc. $NTRA

Krilogy Financial LLC bought a new stake in shares of Natera, Inc. (NASDAQ:NTRA) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 8,219 shares of the medical research company’s stock, valued at approximately $1,323,000.

Other institutional investors also recently modified their holdings of the company. Sound Income Strategies LLC boosted its stake in Natera by 95.7% during the third quarter. Sound Income Strategies LLC now owns 225 shares of the medical research company’s stock worth $39,000 after acquiring an additional 110 shares in the last quarter. Quent Capital LLC purchased a new position in shares of Natera in the 3rd quarter worth about $46,000. Hilltop National Bank boosted its stake in Natera by 59.8% in the 3rd quarter. Hilltop National Bank now owns 310 shares of the medical research company’s stock worth $50,000 after purchasing an additional 116 shares in the last quarter. N.E.W. Advisory Services LLC grew its position in Natera by 256.8% during the 2nd quarter. N.E.W. Advisory Services LLC now owns 314 shares of the medical research company’s stock valued at $53,000 after purchasing an additional 226 shares during the last quarter. Finally, Blue Trust Inc. increased its stake in Natera by 23.1% during the 3rd quarter. Blue Trust Inc. now owns 431 shares of the medical research company’s stock valued at $69,000 after purchasing an additional 81 shares in the last quarter. 99.90% of the stock is currently owned by institutional investors.

Natera Price Performance

NASDAQ NTRA opened at $207.84 on Friday. The stock has a market capitalization of $28.75 billion, a price-to-earnings ratio of -90.76 and a beta of 1.64. Natera, Inc. has a 1-year low of $125.38 and a 1-year high of $256.36. The business’s fifty day moving average price is $231.14 and its 200-day moving average price is $198.16.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the stock. Piper Sandler increased their price target on shares of Natera from $220.00 to $230.00 and gave the company an “overweight” rating in a report on Tuesday, November 11th. BTIG Research increased their target price on Natera from $230.00 to $260.00 and gave the company a “buy” rating in a research note on Friday, December 5th. UBS Group lifted their target price on Natera from $218.00 to $280.00 and gave the stock a “buy” rating in a report on Tuesday, November 18th. JPMorgan Chase & Co. boosted their price target on Natera from $250.00 to $260.00 and gave the stock an “overweight” rating in a research note on Monday, December 15th. Finally, Morgan Stanley upped their price target on Natera from $220.00 to $265.00 and gave the company an “overweight” rating in a report on Monday, December 1st. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Natera has an average rating of “Moderate Buy” and an average target price of $249.20.

Insiders Place Their Bets

In other Natera news, insider Solomon Moshkevich sold 23,205 shares of the business’s stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $234.74, for a total transaction of $5,447,141.70. Following the completion of the sale, the insider directly owned 144,992 shares in the company, valued at $34,035,422.08. The trade was a 13.80% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Roelof Botha sold 75,000 shares of the company’s stock in a transaction dated Monday, November 24th. The shares were sold at an average price of $236.12, for a total transaction of $17,709,000.00. Following the sale, the director directly owned 1,154,198 shares of the company’s stock, valued at $272,529,231.76. The trade was a 6.10% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 455,899 shares of company stock valued at $106,475,440. 5.63% of the stock is currently owned by company insiders.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.